Researchers from The University of Texas MD Anderson Cancer Center demonstrated that an artificial intelligence (AI)-based ...

That approval was based on a phase 3 study that demonstrated a 46% reduction in the risk of disease progression or death, and a 27% reduction in the risk of death compared with Tecentriq alone. In ...

Real-world performance of a multimodal cell-free DNA multi-cancer early detection test in Asian populations.

A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the ...

Abstract: Skin cancer is one of the fastest-growing types of cancer worldwide, and early detection is essential for effective treatment and reduced mortality. Conventional diagnostic techniques take a ...

Thanks to new treatments, some patients with the disease are living longer — leaving them in limbo for years. Thanks to new treatments, some patients with the disease are living longer — leaving them ...

Presentations at the ASCO Annual Meeting 2026 illustrated a strengthening trend toward biomarker-driven, targeted first-line treatments for advanced and metastatic non-small cell lung cancers. Cancers ...

Although cancer treatments are improving fast, prevention has so far been mostly about promoting a healthy lifestyle. But efforts to find preventive drugs and vaccines are starting to bear fruit. New ...

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed.

U.K. pharmaceutical group GSK has entered an agreement to acquire U.S.-based specialist oncology biotech Nuvalent for $10.6 billion. The acquisition could help GSK offset a drop in revenue expected ...

In April, Norway’s Crown Princess Mette-Marit arrived at a royal engagement with an oxygen cannula in her nose. Though she has been public about her diagnosis with pulmonary fibrosis—an irreversible ...

CHICAGO—At the world’s largest oncology conference, Ozempic, a diabetes drug, found its way to the center of the conversation. As thousands of attendees bounced between presentations at the American ...